La cadena de opciones muestra datos clave de las opciones de acciones de Agilon Health a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Agilon Health..

Agilon Health (NYSE:AGL) Bolsa, Cadena de Opciones

AGILON HEALTH INC

Agilon Health

Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AAMI

ACEL

AXON

CDNA

CLIK

ENVB

FLYW

HCTI

ICCT

LBTYK

LMND

NAMS

PITA

PRCH

SMCI

ZoomInfo sorprende con resultados mejores de lo esperado y sus acciones suben un 19,6%. Descubre qué otras acciones se están moviendo hoy.

Acciones de ZoomInfo se disparan un 20%; 20 acciones que se están moviendo en el premercado de EE.UU.

Agilon Health Inc

T2 Metals Corp

Adventure Gold - United States Dollar

AUSTRAL GOLD LTD ORD by Austral Gold Ltd.

Austral Gold Ltd

ANGELALIGN TECH INC by Angelalign Technologies Inc.

Angelalign Technology Inc

AGL Energy Ltd

AGILITY REAL EST NEW by Agility Real Estate Inc.

Agility Capital Holding Inc

ANGEL TELECOM CORP by Angel Telecom Corp.

AgileThought Inc

ATLANTIS GLORY INC by Atlantis Glory Inc.

Atlantis Glory Inc

<ul>
<li>Record May ADV in interest rate, metals and cryptocurrency products</li>
<li>SOFR futures ADV grew 31% over May 2024</li>
<li>International ADV increased 15% to 8.7 million contracts</li>
</ul>
CHICAGO, June 3, 2025 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today reported it reached the highest May average daily volume (ADV) on record at 28.9&nbsp;million contracts, an increase of&nbsp;11% year-over-year. Market statistics are available in greater detail at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440936-1&amp;h=1663060920&amp;u=https%3A%2F%2Fcmegroupinc.gcs-web.com%2Fmonthly-volume&amp;a=https%3A%2F%2Fcmegroupinc.gcs-web.com%2Fmonthly-volume">https://cmegroupinc.gcs-web.com/monthly-volume</a>.
May&nbsp;2025 ADV across asset classes includes:
<ul>
<li>Record May <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440936-1&amp;h=2648253738&amp;u=https%3A%2F%2Fwww.cmegroup.com%2Fmarkets%2Finterest-rates.html%3Fredirect%3D%2Ftrading%2Finterest-rates%2F&amp;a=Interest+Rate">Interest Rate</a> ADV of 16.2 million contracts</li>
<li><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440936-1&amp;h=1996164365&amp;u=https%3A%2F%2Fwww.cmegroup.com%2Fmarkets%2Fequities.html%3Fredirect%3D%2Ftrading%2Fequity-index%2F&amp;a=Equity+Index">Equity Index</a> ADV of 6.6 million contracts</li>
<li><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440936-1&amp;h=2442821376&amp;u=https%3A%2F%2Fwww.cmegroup.com%2Fmarkets%2Fenergy.html%3Fredirect%3D%2Ftrading%2Fenergy%2F&amp;a=Energy">Energy</a> ADV of 2.6 million contracts</li>
<li><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440936-1&amp;h=2478824282&amp;u=https%3A%2F%2Fwww.cmegroup.com%2Fmarkets%2Fagriculture.html%3Fredirect%3D%2Ftrading%2Fagricultural%2F&amp;a=Agricultural">Agricultural</a> ADV of 1.6 million contracts</li>
<li>Record May <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440936-1&amp;h=1563010986&amp;u=https%3A%2F%2Fwww.cmegroup.com%2Fmarkets%2Fmetals.html%3Fredirect%3D%2Ftrading%2Fmetals%2F&amp;a=Metals">Metals</a> ADV of 933,000 contracts</li>
<li><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440936-1&amp;h=3967813048&amp;u=https%3A%2F%2Fwww.cmegroup.com%2Fmarkets%2Ffx.html%3Fredirect%3D%2Ftrading%2Ffx%2F&amp;a=Foreign+Exchange">Foreign Exchange</a> ADV of 893,000 contracts</li>
<li>Record May <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440936-1&amp;h=2370709692&amp;u=https%3A%2F%2Fwww.cmegroup.com%2Fmarkets%2Fcryptocurrencies.html&amp;a=Cryptocurrency">Cryptocurrency</a> ADV of 197,000 contracts ($10 billion notional)</li>
</ul>
Additional May 2025 product highlights compared to May 2024:
<ul>
<li>Interest Rate ADV increased 13%
<ul>
<li>SOFR futures ADV increased 31% to 4 million contracts</li>
<li>U.S. Treasury futures and options&nbsp;ADV increased 6% to 10.6 million contracts</li>
<li>Interest Rate options&nbsp;ADV increased 11% to 2.7 million contracts</li>
</ul>
</li>
<li>Equity Index ADV increased 15%
<ul>
<li>Micro&nbsp;E-mini Nasdaq 100 futures ADV increased 37% to 1.5 million contracts</li>
<li>Micro&nbsp;E-mini S&amp;P 500 futures ADV increased 60% to 1.3 million contracts</li>
</ul>
</li>
<li>Energy ADV increased 6%
<ul>
<li>Record May Energy options&nbsp;ADV of 445,000 contracts</li>
</ul>
</li>
<li>Metals ADV increased 8%
<ul>
<li>Record monthly Micro Gold futures&nbsp;ADV of 347,000 contracts</li>
</ul>
</li>
<li>Cryptocurrency ADV increased 145%
<ul>
<li>Record monthly Ether futures&nbsp;ADV of 17,000 contracts</li>
<li>Micro Ether futures&nbsp;ADV increased 235% to 92,000 contracts</li>
<li>Micro&nbsp;Bitcoin futures ADV increased 95% to 65,000 contracts</li>
</ul>
</li>
<li>Micro Products ADV
<ul>
<li>Micro&nbsp;E-mini Equity Index futures and options ADV of 3 million contracts represented 45.3% of overall Equity Index ADV and Micro WTI Crude Oil futures accounted for 2.5% of overall Energy ADV</li>
</ul>
</li>
<li>International ADV increased 15% to 8.7 million contracts, with EMEA ADV up 14% to 6.4 million contracts and Asia ADV up 24% to 2 million contracts</li>
<li>BrokerTec U.S. Repo average daily notional value (ADNV) increased 28.6% to $352 billion, European Repo ADNV increased 3% to €306.7 billion and U.S. Treasury ADNV increased 20% to $101.1 billion</li>
<li>EBS Spot FX ADNV increased 27% to $67.8 billion and FX Link ADV increased 52% to 43,000 contracts ($2.9 billion notional per leg)</li>
<li>Customer average collateral balances to meet performance bond requirements for rolling 3-months ending April 2025 were $97.2 billion for cash collateral and $162.9 billion for non-cash collateral</li>
</ul>

CME Group May Average Daily Volume Up 11% To 28.9 Mln Contracts From Last Year

As &#8220;Trump Always Chickens Out&#8221; or TACO trade was trending last week, the &#8220;Anywhere But The USA&#8221; or ABUSA trade is also emerging as a notable market trend in 2025, driven by concerns over U.S. economic policies, trade uncertainties, and a global shift toward diversified investment strategies.
What Happened: While the TACO trade signals a widespread belief that Donald Trump&#8216;s possible tariff rollbacks or extensions could be opportunities to buy the dip, the new &#8220;Anywhere But The USA&#8221; or ABUSA trade suggests fleeing the U.S. assets amid uncertainties and chaotic policy changes.
According to a 2024 <a href="https://carnegieendowment.org/research/2024/05/time-to-reset-the-us-trade-agenda?lang=en">report</a> by Carnegie Endowment for International Peace, former U.S. Trade Representative Robert Lighthizer, the architect of Trump's 2017-2021 trade policy, advocated for tariffs to protect U.S. industries and pressure other countries to cease unfair trade practices.
However, experts cited in the report warn that such policies could isolate the U.S. economically, driving investors to look elsewhere, aligning with the ABUSA narrative.
Meanwhile, Alan Siow, the investment manager at Ninety One, <a href="https://www.cnbc.com/2025/06/02/inside-the-abusa-trade-anywhere-but-the-usa.html">told</a> CNBC that ABUSA trade is a &#8220;recalibration toward global balance, cyclical recovery, and multi-polar growth&#8221; rather than a contrarian move
He argues that the trade reflects a decade-long shift away from a &#8220;widespread preference for U.S.&#8221; assets, driven by seesawing trade policies, proposed foreign capital taxes, and concerns over U.S. fiscal spending.
Siow's perspective emphasizes a structural change in investor behavior, where the U.S. is no longer the default safe haven.
He sees ABUSA as a logical response to a U.S. economic environment perceived as increasingly risky due to policy flip-flops, such as Trump's tariff threats and retreats, linked to the TACO trade, and a dollar selloff that has made non-U.S. markets more attractive. While these strategies promote the &#8220;Sell America&#8221; narrative, an LPL Financial note added that fear of asset sales from the &#8220;de-dollarization&#8221; and &#8220;Sell America&#8221; is also a potential headwind to Treasury yields.
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/45739065/sp-500-reverses-short-term-downtrend-after-april-lows-technical-evidence-shows-recovery-is-real-and-not-a-bull-trap-or-bear-market-rally">S&amp;P 500 Reverses Short-Term Downtrend After April Lows: Technical Evidence Shows &#8216;Recovery Is Real&#8217; And Not A &#8216;Bull Trap&#8217; Or &#8216;Bear Market Rally&#8217;</a>
Why It Matters: Rami Cassis, the founder of London's Parabellum, also added another perspective to the rise in ABUSA trade, describing the reaction of investors toward the U.S. as &#8220;emotive.&#8221;
According to Cassis, beyond his unpredictable trade policies, a number of other contentious stances held by Trump, including his approach to the conflict in Ukraine and his position on LGBTQIA+ rights, also played a role in discouraging some individuals from investing in America.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Tuesday. The SPY was down 0.38% at $590.45, while the QQQ declined 0.36% to $521.32, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/treasuries/25/06/45739830/us-dollar-decouples-with-10-year-treasuries-as-trade-tensions-change-long-standing-relationships-between-asset-classes">US Dollar Decouples With 10-Year Treasuries As Trade Tensions Change Long-Standing Relationships Between Asset Classes </a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

TACO Trade To 'Anywhere But The USA': Viral Trends Echo 'Sell America' Amid Tumultuous Federal Policies

US drug giant Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a bid exceeding $3 billion.
While MoonLake turned down the initial offer, talks may be revived.
The potential deal signals renewed dealmaking activity as investor pressure has mounted on Merck to secure new assets, especially as its blockbuster <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">cancer drug Keytruda</a> faces patent expiration as early as 2028.
MoonLake Immunotherapeutics&#8217; lead development asset sonelokimab is a novel investigational Nanobody&nbsp;for inflammatory diseases.
Also Read: <a href="https://www.benzinga.com/news/health-care/25/05/45701905/merck-kandlelit-trials-spark-hope-lung-cancer-trials" target="_blank" rel="noreferrer noopener">Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers</a>
Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.
Merck is also grappling with <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44983460/mercks-q1-earnings-beat-wall-street-adjusts-2025-profit-outlook-as-tariffs-may-result-in-incremental-cost-of-200-million" rel="noreferrer noopener">falling sales of its Gardasil</a> vaccine in China and underwhelming uptake of its new hypertension drug, Winrevair.
Per a Financial Times <a target="_blank" href="https://www.ft.com/content/5899ea69-e5fe-49f1-8ada-79f26c9254d8" rel="noreferrer noopener">report</a> on Monday, Merck made a nonbinding offer earlier this year, valuing MoonLake above its $2.6 billion market capitalization.
Founded in 2021 by former McKinsey partner Jorge Santos da Silva, MoonLake has garnered investor interest, with its stock price climbing nearly 50% over the past two years.
The FT report added that the company hired Goldman Sachs and Morgan Stanley to advise on the sale process.
Over the past year, Merck shares have dropped 39%, significantly underperforming the broader S&amp;P 500 pharmaceutical index, which declined by 11%.
In April, MoonLake Immunotherapeutics entered into an agreement with Hercules Capital, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NASDAQ">HTGC</a>) for up to $500 million in non-dilutive capital, of which $75 million will be drawn down at close and additional tranches will become available upon achievement of certain pre-specified milestones that are aligned with MoonLake&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44624282/moonlake-secures-up-to-500-million-in-non-dilutive-financing-from-hercules-capital-and-announces-a" rel="noreferrer noopener">strategy and funding needs</a>.
In January, MoonLake announced that patients have been screened in three new trials across three new indications <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42869804/moonlake-initiates-three-new-clinical-trials-and-further-expands-the-portfolio-of-indications-for-" rel="noreferrer noopener">to evaluate sonelokimab</a>.
The clinical program for sonelokimab now includes patients with adolescent hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP), and axial spondyloarthritis (axSpA), as well as adult patients with HS and active psoriatic arthritis (PsA).
This increases the number of clinical trials led by MoonLake to ten and aligns with the company&#8217;s plan to enroll over 3,000 patients in clinical trials with sonelokimab since its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45358838/moonlake-immunotherapeutics-reports-first-quarter-2025-financial-results-and-provides-a-business-u" rel="noreferrer noopener">founding in 2021</a>.
Price Action: MLTX stock is trading higher by 21.1% to $49.84 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/45731052/warner-bros-debt-downgrade-is-an-ironically-positive-event-analyst" target="_blank" rel="noreferrer noopener">Warner Bros&#8217; Debt Downgrade Is An &#8216;Ironically Positive&#8217; Event: Analyst</a></li>
</ul>
Photo by tada images via Shutterstock

Biotech

Health Care

Rumors

General

HTGC

MLTX

Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report

Canaccord Genuity analyst Whitney Ijem maintains Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) with a Buy and raises the price target from $9 to $11.

Price Target

Analyst Ratings

TSHA

Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Raises Price Target to $11

Energys Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGS#NASDAQ">ENGS</a>) ("Energys Group" or the "Company", together with its subsidiaries, the "Group"), a vertically integrated energy efficiency and decarbonisation solutions provider for the built environment, is pleased to announce the award of the second tranche of LED lighting projects from Ark Multi-Academy Trust ("Ark"), an education charity based in London, United Kingdom.
The LED lighting projects involve upgrading existing infrastructure with the latest generation of LED lighting systems and intelligent controls. Upon completion, the projects are expected to deliver annual savings of approximately £1.4 million and reduce carbon emissions by over 900 tonnes annually. To date, the Company has completed Phase I of the projects, valued at £1.2 million. Riding on the successful completion and its proven track record, the Company has secured an additional&nbsp;£1.1 million in contracts which will commence immediately, along with £1.2 million for works scheduled for August 2025. A further £2.0 million later in 2025 is anticipated to finalise the programme, bringing the total value of works to £5.5 million.

ENGS

Energys Group Awarded Second Tranche Of LED Lighting Projects From Ark Multi-Academy Trust

RVSN

Rail Vision Lands $335K Follow-Up Order From Top Latin American Miner

Guidance

OLLI

Ollie's Bargain Outlet Affirms FY2025 Adj EPS Guidance of $3.65-$3.75 vs $3.73 Est; Raises FY2025 Sales Guidance from $2.56B-$2.59B to $2.58B-$2.60B vs $2.58B Est

Canaccord Genuity analyst Whitney Ijem maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Buy and lowers the price target from $34 to $11.

RCKT

Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $11

TSLA reverses early down move after signal from TradePulse
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02212102/Screenshot-2025-06-02-at-5.18.27%E2%80%AFPM-1-1024x1009.png" alt="" class="wp-image-13760" /></figure>
Tesla lnc. (TSLA) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 11:00 AM on June 2nd, a significant trading signal occurred for Tesla Inc., (TSLA) as it demonstrated a Power Inflow at a price of $337.32. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Tesla's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Tesla's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for TSLA, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_May2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_May2025</a> which are responsible for parts of the data within this article.
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close UPDATE:
The price at the time of the Power Inflow was $337.32. The returns on the High price ($342.75) and Close price ($342.69) after the Power Inflow are respectively 1.6% and 1.59%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.They were close today but is not always the case
Results are not indicative of future results

Equities

Technicals

Opinion

Signals

TSLA

Tesla Rises 1.6% After Power Inflow Signal

- Newly issued patent includes claims to novel formulations of N,N-dimethyltryptamine ("DMT") and deuterated isotopologues for intramuscular injection, including CYB004, with expected exclusivity until 2040 -
- Cybin's growing intellectual property portfolio comprises more than 90 granted patents and over 230 pending applications -
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cybin.com%2F&amp;esheet=54264056&amp;newsitemid=20250603724552&amp;lan=en-US&amp;anchor=Cybin&amp;index=1&amp;md5=9893a04fd89d51c1e361a5d6057c93f2">Cybin</a> Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#NYSE">CYBN</a>) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,318,477 in support of its CYB004 deuterated DMT program in development for the treatment of generalized anxiety disorder ("GAD").
The patent, which is expected to provide exclusivity until 2040, includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ("IM") injection, including CYB004.

CYBN

Cybin Granted U.S. Patent For CYB004 Deuterated DMT In Development For Treatment Of Generalized Anxiety Disorder

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Buy and lowers the price target from $74 to $54.

NTLA

Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $54

Rekor Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REKR#NASDAQ">REKR</a>) (the "Company"), a leader in developing and implementing state-of-the-art roadway intelligence technology, today announced it has been selected for a multi-year statewide contract by the Texas Department of Transportation (TxDOT). The award approves the implementation of <a href="https://www.globenewswire.com/Tracker?data=CKb5i6i4782bwy7hpFCvlbzKSvg94YIJn02ixSBTEyX8ch1hfUn_ksnGXFVSQWy16VQFM7YiCN8iH_jocKD2pOZztI9Nr8umtSvpBC6Q9C8=">Rekor Command</a>&#xAE;— the Company's advanced incident management and situational awareness platform, to enhance traffic operations, reduce congestion, and improve roadway safety. It includes an eight-figure blanket purchase order that pre-authorizes all TxDOT metropolitan, urban, and rural districts to immediately adopt the technology.
Texas operates the largest state-maintained roadway network in the United States, with over 80,000 miles of highways. As population growth and traffic volumes accelerate, particularly in six of the ten fastest-growing counties in the nation, TxDOT faces increasing pressure to enhance roadway operations, reduce congestion, and improve safety outcomes. Texas has consistently led the nation in adopting cutting-edge transportation technologies, from smart infrastructure to real-time data systems, making it an ideal state for deploying Rekor's next-generation platform at scale.
TxDOT Director of Strategy and Innovation Darran Anderson stated, "We look forward to continuing our partnership with Rekor to expand the deployment and use of advanced roadway insights powered by big data and intelligent systems to help address safety and congestion across Texas."&nbsp;
Rekor Command&#xAE; has already demonstrated success in Texas. Initially deployed by the TxDOT Austin District two years ago, the platform underwent an extended, data-driven evaluation that confirmed major operational improvements, including:
<ul>
<li>159% increase in incident detection</li>
<li>8.4-minute reduction in median incident detection time</li>
<li>83% incident detection accuracy</li>
<li>44-minute reduction in incident clearance time</li>
<li>29% reduction in secondary crashes Rekor Command&#xAE; unifies disparate data sources into a single, AI-powered platform that enhances situational awareness, supports faster decision-making, and improves resource allocation. Replacing an array of diverse and fragmented tools with a single platform that delivers real-time insights and powerful decision support enables transportation agencies to proactively manage roads, allocate resources efficiently, and respond faster to incidents.</li>
</ul>
Under this expanded contract, TxDOT will also deploy several new features, including:
<ul>
<li>Traffic Impact Module – A first-of-its-kind decision support tool that uses AI to assess and visualize how incidents affect traffic flow in real-time and provide real-time insights to operators for proactive and strategic operations, faster response times, and improved traffic safety, ultimately enhancing overall network performance.</li>
<li>Work Zone API – Enhances safety by delivering accurate, real-time insights into work zone activity, improving visibility for TxDOT operators and the public. The platform also integrates with the USDOT FHWA's Work Zone Data Exchange (WZDx), enabling standardized, open data sharing across local and national systems to support broader safety and mobility goals. By making critical work zone information more accessible and actionable, the platform supports safer construction zones, enhances roadway travel time reliability, and strengthens agency coordination.</li>
</ul>
Rekor Command&#xAE; will also continue to serve as the data backbone for TxDOT's Construction Partnership Program (CPP), a foundational data layer for improving regional collaboration, public communication, and traffic management. With this statewide expansion, Rekor's role within the CPP will grow to support additional objectives, most notably by powering the CTX-GO mobile application. Built on real-time data streams from the Rekor platform, CTX-GO delivers timely, unified information to travelers, contractors, and public agencies, ensuring enhanced situational awareness and seamless coordination across Texas's growing infrastructure network.
This contract reinforces Rekor's growing role as a trusted partner to large-scale transportation agencies. As Texas modernizes its infrastructure, Rekor Command&#xAE; will help drive smarter, safer, and more resilient roadways across the state.

REKR

Rekor Systems Chosen For Multi-Year Statewide Contract By Texas Department Of Transportation

Earnings

Retail Sales

Ollie's Bargain Outlet's Q1 2025 Comparable Store Sales Increased 2.6%

NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.37) by 10.81 percent. This is a 24.24 percent decrease over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $1.66 billion which missed the analyst consensus estimate of $1.73 billion by 4.16 percent. This is a 20.82 percent increase over sales of $1.37 billion the same period last year.

Earnings Misses

NIO Q1 Adj. EPS $(0.41) Misses $(0.37) Estimate, Sales $1.66B Miss $1.73B Estimate

Ollie's Bargain Outlet Q1 2025 Adj. EPS $0.75 Beats $0.71 Estimate, Sales $576.77M Beat $565.95M Estimate

Redwire Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>), a leader in space infrastructure for the next generation space economy, announced today that it has been awarded a contract from Aspera Biomedicines, Inc. (Aspera), a pharmaceutical company specializing in the development of cancer stem cell targeted therapies, to conduct space-based research and analysis on a new cancer treatment using Redwire's Pharmaceutical In-space Laboratory (PIL-BOX) technology.
Aspera will use this mission to advance development of rebecsinib, a small molecule ADAR1 inhibitor recently approved by the U.S. Food and Drug Administration to begin first-in-human trials. On Earth, scientists have noted an upregulation – or increased rate of expression – of the ADAR1 protein in cancer stem cells as being linked to the accelerated progression of some types of cancer. Researchers at Aspera have analyzed data from two previous spaceflight experiments that showed that rebecsinib can inhibit expression of ADAR1, halting the progression of cancer stem cell propagation in triple-negative breast cancer organoid models. Results from Aspera's prior experiments indicate that rebecsinib could behave as a cancer "kill switch."
On this mission, Aspera researchers will analyze the crystal structure of ADAR1p150 with and without rebecsinib or intermediates. The results of this analysis could enhance opportunities to develop new drug formulations and a broader array of ADAR1 inhibitors.

Redwire Bags Contract From Aspera Biomedicines To Conduct Space-Based Research And Analysis On New Cancer Treatment Using Redwire's PIL-BOX Technology

As of June 3, 2025, two stocks in the consumer discretionary sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to<a href="https://pro.benzinga.com/"> Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Signet Jewelers Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>)</h3>
<ul class="wp-block-list">
<li>On June 3, Signet Jewelers posted better-than-expected quarterly earnings. &#8220;We delivered positive same store sales growth each month of the quarter, and into May, by bolstering our offerings at key price points and continuing the evolution of our assortment. Our three largest brands – Kay, Zales, and Jared – all saw sequential comp sales improvement from the fourth quarter on higher margins, highlighting the impact of our outsized focus on our larger brands,&#8221; said J.K. Symancyk, Chief Executive Officer. The company's stock jumped around 10% over the past month and has a 52-week high of $112.06.</li>
<li>RSI Value: 73.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>SIG Price Action: Shares of Signet gained 0.4% to close at $66.81 on Monday.</li>
<li>Edge Stock Ratings: 14.34 Momentum score with Value at 87.25. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/sig"><img loading="lazy" decoding="async" width="476" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03072225/image-25.png" alt="" class="wp-image-936482" style="width:390px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03072225/image-25.png 476w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03072225/image-25-300x115.png 300w" sizes="(max-width: 476px) 100vw, 476px" /></a></figure>
<h3 class="wp-block-heading">Cricut Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>)</h3>
<ul class="wp-block-list">
<li>On May 6, Cricut reported better-than-expected first-quarter financial results. &#8220;We are pleased with the increase in paid subscribers in Q1 up 6% year-over-year, the continuation of positive International sales growth up 8% year-over-year and strong profitability,&#8221; said Ashish Arora, Chief Executive Officer of Cricut. The company's stock gained around 25% over the past month and <a href="https://www.benzinga.com/quote/CRCT">has a 52-week high</a> of $7.17.</li>
<li>RSI Value: 70.4</li>
<li>CRCT Price Action: Shares of Cricut rose 4.5% to close at $6.33 on Monday.</li>
</ul>
Don't miss out on the full BZ Edge Rankings—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">compare all the key stocks now</a>. 
Read This More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45719976/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Short Ideas

CRCT

Top 2 Consumer Stocks That Could Sink Your Portfolio In Q2

D. Boral Capital analyst Jesse Sobelson maintains MultiSensor AI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSAI#NASDAQ">MSAI</a>) with a Buy and maintains $2.5 price target.

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

D. Boral Capital Maintains Buy on MultiSensor AI Holdings, Maintains $2.5 Price Target

NIO Sees Q2 Sales $2.689B-$2.765B vs $25.60B Est

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) with a Buy and maintains $30 price target.

IBRX

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

Press Releases

agilon health Reports ACO REACH Model Results for 2023 Performance Year

Legal

Agilon Health, Inc, B. Riley Financial, Target Corporation, and Getty Images Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

agilon health Sets Date to Report Fourth Quarter and Full Year 2024 Financial Results

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of agilon health, inc. (NYSE: AGL) and Encourages Long-Term Investors to Contact the Firm

agilon health to Participate in TD Cowen's 45th Annual Health Care Conference

agilon health Reports Fourth Quarter and Full Year Fiscal 2024 Results

agilon health Sets Date to Report First Quarter 2025 Financial Results

agilon health to Participate in BofA Securities 2025 Health Care Conference

agilon health Reports First Quarter 2025 Results

agilon health to Participate in Bernstein's 41st Annual Strategic Decisions Conference

GETY

RILY

Addus HomeCare Corporation - Common Stock

Addus HomeCare

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

Amedisys

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Comments

Agilon Health

Agilon Health (AGL) Opciones

Agilon Health (NYSE:AGL) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL